Nirav Thacker

Dr. Nirav Thacker


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2024 in Current Oncology
Verified
Journal Article
Open access
PDF file
Craig ErkerCraig Erker
Craig Erker
MVMagimairajan Issai Vanan
Magimairajan Issai Vanan
VLValérie Larouche
Valérie Larouche
LNLiana Nobre
Liana Nobre
CCChantel Cacciotti
Chantel Cacciotti
Sébastien PerreaultSébastien Perreault
Sébastien Perreault
Background: The treatment of BRAF V600E gliomas with BRAF inhibitors (BRAFis) and MEK inhibitors (MEKis) has been increasingly integrated into clinical practice for pediatric low-grade gliomas (PLGGs) and pediatric high-grade gliomas (HGGs). However, some questions remain unanswered, such as the best time to start targeted therapy, duration of treatment, and discontinuation of therapy. Given that no clinical trial has been able to address these critical questions, we developed a Canadian Consensus statement for the treatment of BRAF V600E mutated pediatric as well as adolescent and young adult (AYA) gliomas. Methods: Canadian neuro-oncologists were invited to participate in the development of this consensus. The consensus was discussed during monthly web-based national meetings, and the algorithms were revised until a consensus was achieved. Results: A total of 26 participants were involved in the development of the algorithms. Two treatment algorithms are proposed, one for the initiation of treatment and one for the discontinuation of treatment. We suggest that most patients with BRAF V600E gliomas should be treated with BRAFis ± MEKis upfront. Discontinuation of treatment can be considered in certain circumstances, and we suggest a slow wean. Conclusions: Based on expert consensus in Canada, we developed algorithms for treatment initiation of children and AYA with BRAF V600E gliomas as well as a discontinuation algorithm.

15 May 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
SRSamuele Renzi
Samuele Renzi
JBJulie Bennett
Julie Bennett
NTNirav Thacker
Nirav Thacker
CCChantel Cacciotti
Chantel Cacciotti
Pediatric gliomas encompass the most common brain tumor in children and are subdivided into pediatric low-grade gliomas (pLGGs) and pediatric high-grade gliomas (pHGGs). The era of molecular diagnosis has shifted the treatment paradigms and management of these patients. RAS/MAPK pathway alterations serve as the driver in the majority of pLGGs, a subset of pHGG and NF1-related plexiform neurofibromas (PNs). The role of small molecule inhibitors in the treatment of these tumors has evolved in the past decade, facilitated through multiple clinical trials and moving into earlier stages of treatment. Although these developments hold promise, questions remain regarding targeted therapy, the long-term toxicities, the duration of treatment and the potential effects on the natural history of the tumor behavior.

23 October 2024
Verified
Book Chapter
Closed access
PDF file
JKJohn-Paul Kilday
John-Paul Kilday
JHJuliette Hukin
Juliette Hukin
NTNirav Thacker
Nirav Thacker
UTUri Tabori
Uri Tabori
Vijay RamaswamyVijay Ramaswamy
Vijay Ramaswamy

31 August 2026 in Current Oncology
Verified
Journal Article
Open access
PDF file
IYIrem Yenidogan
Irem Yenidogan
NTNirav Thacker
Nirav Thacker
ADAnirban Das
Anirban Das
MVMagimairajan Issai Vanan
Magimairajan Issai Vanan
Brain tumors are the most common solid malignancies in children and the leading cause of cancer-related mortality in this age group. Cancer immunotherapy has shown a lot of promise in the treatment of both adult and pediatric cancers. In this review, we summarize the use of immunotherapies in the treatment of pediatric brain tumors with special emphasis on CAR T cells, Immune checkpoint inhibitors and oncolytic viral therapy.